---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-23-000060"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T01:56:47.963352+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Integra Q2 adj EPS $0.71, revenue $381M (-4.2%); FDA warning on Boston facility; guides down

## Summary
- Q2 GAAP diluted EPS $0.05 vs $0.54; adjusted EPS $0.71 vs $0.82; revenue $381.3M declined 4.2% reported, 2.7% organic.
- Codman Specialty Surgical organic growth 6.3%; Tissue Technologies organic decline 19.7% due to Boston recall impact.
- FDA warning letter (July 17, 2023) for Boston facility quality systems; does not restrict shipping but requires annual third-party audit for three years.
- Planning $125M share repurchase in Q3 under new $225M board authorization; replaced prior program.
- Updated FY2023 guidance: revenue $1.548-1.560B, adj EPS $3.10-3.18; Boston restart late Q4'23, commercial distribution mid-Q2'24.

## SEC filing metadata
- accession: 0000917520-23-000060
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/iart-20230726.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-23-000060
- JSON: https://secwatch.observer/filing/0000917520-23-000060.json
- Plain text: https://secwatch.observer/filing/0000917520-23-000060.txt

## Key facts
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported the quarter ended June 30, 2023 results: revenue $381.3 million, net income $4.2 million, EPS $0.05 per diluted share.
  - Period: the quarter ended June 30, 2023
  - Revenue: $381.3 million
  - Net income: $4.2 million
  - EPS: $0.05 per diluted share
  - Result: reported results
  source text: Total reported revenues of $381.3 million declined 4.2% on a reported basis and declined 2.7% on an organic basis compared to the prior year. The Company reported GAAP gross margin of 54.3%, compared to 62.7% in the second quarter of 2022. Adjusted gross margin was 67.6%, compared to 68.0% in the prior year. Adjusted EBITDA for the second quarter of 2023 was $88.8 million, or 23.3% of revenue, compared to $102.8 million, or 25.8% of revenue, in the prior year. The Company reported GAAP net income of $4.2 million, or $0.05 per diluted share, in the second quarter of 2023, compared to a GAAP net income of $44.8 million, or $0.54 per diluted share, in the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported full year 2023 results: revenue $1.548 billion to $1.560 billion, EPS $3.10 to $3.18.
  - Period: full year 2023
  - Revenue: $1.548 billion to $1.560 billion
  - EPS: $3.10 to $3.18
  - Result: guidance update
  source text: Updating full-year 2023 revenue and adjusted earnings per share guidance with a range of $1.548 billion to $1.560 billion and $3.10 to $3.18 respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm
- Earnings Releases
  INTEGRA LIFESCIENCES HOLDINGS CORP reported the third quarter 2023 results: revenue $386 million to $390 million, EPS $0.76 to $0.80.
  - Period: the third quarter 2023
  - Revenue: $386 million to $390 million
  - EPS: $0.76 to $0.80
  - Result: guidance update
  source text: For the third quarter 2023, the Company expects reported revenues in the range of $386 million to $390 million, representing reported growth of 0.2% to 1.3 % and organic growth of 0.3% to 1.3 % . Adjusted earnings per diluted share are expected to be in the range of $0.76 to $0.80
  evidence_url: https://www.sec.gov/Archives/edgar/data/917520/000091752023000060/0000917520-23-000060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.